Conference Coverage
Conference Coverage
Aspirin didn’t extend survival in PIK3CA-mutant colorectal cancer
Major finding: With a median follow-up of 46 months, the 26% of the study population who were regular aspirin users and the non-users had...
Conference Coverage
New chemo regimen is active against recalcitrant neuroendocrine tumors
Major finding: The overall response rate was 43% and the clinical benefit rate was 97%. Data source: A randomized phase II trial among 28 patients...
Conference Coverage
Dual-vaccine therapy prolonged survival in pancreatic cancer
Major Finding: Compared with GVAX alone, GVAX followed by CRS-207 was associated with better overall survival (6.1 vs. 3.9 months; hazard ratio, 0...
Conference Coverage
ONO-4059 makes waves in heavily pretreated CLL
Major finding: The response rate was 89% overall and 71% for patients with 17p deletion. Data source: A prospective, phase I dose-escalation study...
Conference Coverage
Lower-dose quizartinib diminishes QT events
Major finding: An increase in QTcF from baseline of more than 60 msec was seen in 19% of patients on quizartinib 60 mg and in 3% of those on 30 mg...
Conference Coverage
Anticoagulation reaped survival benefit in leukemia patients with DVT
Major finding: Median survival has not been reached in the anticoagulation group and was 9 months in controls (P = .02).Data source: A...
Conference Coverage
CAR-T cells drive ALL into remission
Major finding: Anti-CD19 chimeric antigen receptor T cells induced complete responses in 10 of 16 children and young adults with relapsed/...
Conference Coverage
Findings set stage for immunomodulatory approaches in breast cancer
Major finding: For every 10% increment in stromal tumor-infiltrating lymphocytes present at the time of diagnosis of HER2-positive breast cancer,...
Conference Coverage
Add-on agents boost neoadjuvant chemo response in triple-negative disease
Major finding: Carboplatin improved the odds of pCR by 71%-76% with some additional toxicity; bevacizumab improved the odds of pCR by 58% with...
Conference Coverage
Veliparib-carboplatin combo is first 'graduate' of I-SPY2 trial
Major finding: Among patients with triple-negative disease, there was a 90% predictive probability that veliparib-carboplatin added to...
Conference Coverage
Exercise dampens aromatase inhibitor–related joint pain
Major finding: Breast cancer patients experienced a 30% reduction in aromatase inhibitor–related joint pain, with pain scores going from moderate...